Efficacy and safety of baricitinib in rheumatoid arthritis patients with moderate renal impairment: a multicenter propensity score matching study.

Autor: Maeyama A; Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan. akira.maeyama0713@joy.ocn.ne.jp., Kondo M; Kondo Clinic of Rheumatology and Orthopaedic Surgery, 3-10-11 Tenjin, Chuo-ku, Fukuoka, 810-0001, Japan., Harada H; Department of Orthopaedic Surgery Rheumatology Center, Yagi Hospital, 2-21-25, Maidashi, Higashi-ku, Fukuoka, 812-0054, Japan., Shono E; Shono Rheumatology Clinic, Nishijin Prime Building, 1-10-27, Nishijin, Sawara-ku, Fukuoka, 814-0002, Japan., Nagamine R; Nagamine Rheumatology and Orthopaedic Clinic, 1-11-1, Kashiiekimae, Higashi-ku, Fukuoka, 813-0013, Japan., Tsuru T; PS Clinic, Random Square, 6-18 Tenya-cho, Hakata-ku, Fukuoka, 812-0025, Japan., Inoue Y; Department of Rheumatology, Fukuoka Red Cross Hospital, 3-1-1 Ogusu, Minami-ku, Fukuoka, 815-8555, Japan., Nakashima M; Division of Rheumatology, Kurume University Medical Center, 155-1 Kokubu-machi, Kurume, 839-0863, Fukuoka, Japan., Yamasaki Y; Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan., Niiro H; Department of Medical Education, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan., Nakashima Y; Department of Orthopaedic Surgery, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan., Yamamoto T; Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.
Jazyk: angličtina
Zdroj: BMC rheumatology [BMC Rheumatol] 2024 Dec 18; Vol. 8 (1), pp. 69. Date of Electronic Publication: 2024 Dec 18.
DOI: 10.1186/s41927-024-00446-y
Abstrakt: Background: This study aimed to compare the efficacy and safety of baricitinib in patients with rheumatoid arthritis (RA) receiving different doses based on renal function.
Methods: We conducted a retrospective study within the JAK Study Group, involving 23 facilities in Fukuoka Prefecture, examining patients treated with baricitinib for RA. Patients were categorized into two dose groups: 4 mg with normal/mild renal dysfunction and 2 mg with moderate renal dysfunction. Baricitinib's efficacy, retention rate, and safety were compared between the groups after propensity score matching.
Results: After propensity score matching, disease duration, methotrexate dosage, and anti-cyclic citrullinated peptide antibody positivity rate were balanced across 33 patients in both groups. No significant differences were observed between the groups in tender/swollen joint counts, changes in evaluator/patient global assessments, achievement rate of low disease activity, remission rate on clinical/simplified disease activity indices, or retention rate. Additionally, the incidence of adverse events aligned with previous reports, indicating similar drug safety profiles.
Conclusions: Baricitinib 2 mg in RA patients with moderate renal dysfunction showed comparable efficacy and retention rate to 4 mg in patients with normal/mild renal dysfunction. The incidence and types of adverse events were consistent with previous studies, indicating the safety of the drug at these dosages.
Competing Interests: Declarations. Ethics approval and consent to participate: This study was conducted with the approval of the Ethics Review Committee (Haradoi Hospital Ethical Review Board: Approval No. 2019006). This study is a multicenter study. In addition, Haradoi Hospital was the institute of the Ethical Review Committee decided by the Kondo Clinic of Rheumatology and Orthopaedic Surgery, the lead institution of the study. All the patients provided informed verbal consent to participate in this study. The procedure of obtaining informed verbal consent was approved by Haradoi Hospital Ethical Review Board. Consent for publication: Not applicable. Competing interests: HN has received lecture fees or grants from Asahi Kasei Pharma Corporation, Eisai Co., Ltd., GlaxoSmithKline K.K., Bristol Myers Squibb, Nippon Boehringer Ingelheim Co., Ltd. and Chugai Pharmaceutical Co., Ltd. The other authors have no competing interests to declare.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: